BNGO Stock Overview
Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$2.27 |
| 52 Week Low | US$0.20 |
| Beta | 2.38 |
| 11 Month Change | -34.66% |
| 3 Month Change | -59.54% |
| 1 Year Change | -85.56% |
| 33 Year Change | -99.49% |
| 5 Year Change | -97.83% |
| Change since IPO | -99.70% |
Recent News & Updates
Shareholder Returns
| BNGO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -24.4% | -5.8% | -1.0% |
| 1Y | -85.6% | 1.7% | 30.3% |
Return vs Industry: BNGO underperformed the US Life Sciences industry which returned 1.7% over the past year.
Return vs Market: BNGO underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 10.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BNGO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BNGO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 344 | Robert Holmlin | www.bionano.com |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics, Inc. Fundamentals Summary
| BNGO fundamental statistics | |
|---|---|
| Market cap | US$21.53m |
| Earnings (TTM) | -US$135.78m |
| Revenue (TTM) | US$33.33m |
0.6x
P/S Ratio-0.1x
P/E RatioIs BNGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNGO income statement (TTM) | |
|---|---|
| Revenue | US$33.33m |
| Cost of Revenue | US$33.93m |
| Gross Profit | -US$599.00k |
| Other Expenses | US$135.18m |
| Earnings | -US$135.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | -1.80% |
| Net Profit Margin | -407.34% |
| Debt/Equity Ratio | 30.6% |
How did BNGO perform over the long term?
See historical performance and comparison